Sarah M. Leatherman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah M. Leatherman has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Hau
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, MA 02111, USA
10 shared publications - Ryan Ferguson
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, MA 02111, USA
8 shared publications Ryan E. Ferguson
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System
7 shared publicationsAreef Ishani
Minneapolis VA Healthcare System, Minneapolis, USA
6 shared publications- Areef Ishani
Minneapolis VAHCS: Minneapolis VA Medical Center, Minneapolis, Minnesota
6 shared publications Peter A. Glassman
Pharmacy Benefits Management Services, Department of Veterans Affairs
6 shared publications
Latest Publications
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
β-Blockers in Hemodialysis Outcome Trial
Was not provided for this article.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
β-Blockers in Hemodialysis Outcome Trial
Was not provided for this article.
- Open Access
- 17 September 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (9) , 1230
Validity of EHR-Derived Phenotypes for Outcome Ascertainment in the PRESERVE Trial: Implications for Embedding RCTs in Healthcare Systems
Randomized controlled trials (RCTs) are crucial for determining effective interventions but are costly, time-consuming, and complex. Electronic health records (EHRs) offer the potential to enhance research using clinical data, reducing costs and improving efficiency. We evaluated the accuracy of EHR-derived phenotypes for endpoint identification versus RCT-outcome ascertainment in the PRESERVE trial (NCT01467466), comparing sodium bicarbonate vs. sodium chloride and oral acetylcysteine vs. placebo in preventing serious adverse outcomes and contrast-associated acute kidney injury (CIAKI) after angiography. PRESERVE outcomes were compared with EHR data from the Veterans Affairs Corporate Data Warehouse. Real-world data (RWD) phenotypes captured serious adverse events within 90 days post-angiography, including death, dialysis need, and persistent kidney decline. Sensitivity, specificity, and percent agreement were calculated using trial outcomes as the gold standard. Among 4,196 PRESERVE patients, 95% had outcomes assessed. RWD outcomes showed mixed accuracy: 100% sensitivity/specificity for death; high sensitivity for primary composite events (71.2%), dialysis (75.0%), and hospitalization (78.1%); and low sensitivity for CIAKI (45.8%) and persistent kidney decline (40.5%). Substituting RWD outcomes into primary analysis produced conclusions matching the RCT conclusions. EHR phenotypes can substitute for traditional outcome collection, given adequate planning and validation. Despite variable accuracy, RWD outcomes yielded similar conclusions to RCTs, supporting their use for trial efficiency and reducing costs.
- 17 September 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (9) , 1230
Open AccessValidity of EHR-Derived Phenotypes for Outcome Ascertainment in the PRESERVE Trial: Implications for Embedding RCTs in Healthcare Systems
Randomized controlled trials (RCTs) are crucial for determining effective interventions but are costly, time-consuming, and complex. Electronic health records (EHRs) offer the potential to enhance research using clinical data, reducing costs and improving efficiency. We evaluated the accuracy of EHR-derived phenotypes for endpoint identification versus RCT-outcome ascertainment in the PRESERVE trial (NCT01467466), comparing sodium bicarbonate vs. sodium chloride and oral acetylcysteine vs. placebo in preventing serious adverse outcomes and contrast-associated acute kidney injury (CIAKI) after angiography. PRESERVE outcomes were compared with EHR data from the Veterans Affairs Corporate Data Warehouse. Real-world data (RWD) phenotypes captured serious adverse events within 90 days post-angiography, including death, dialysis need, and persistent kidney decline. Sensitivity, specificity, and percent agreement were calculated using trial outcomes as the gold standard. Among 4,196 PRESERVE patients, 95% had outcomes assessed. RWD outcomes showed mixed accuracy: 100% sensitivity/specificity for death; high sensitivity for primary composite events (71.2%), dialysis (75.0%), and hospitalization (78.1%); and low sensitivity for CIAKI (45.8%) and persistent kidney decline (40.5%). Substituting RWD outcomes into primary analysis produced conclusions matching the RCT conclusions. EHR phenotypes can substitute for traditional outcome collection, given adequate planning and validation. Despite variable accuracy, RWD outcomes yielded similar conclusions to RCTs, supporting their use for trial efficiency and reducing costs.
- Open Access
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e046142
Per‐Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention—Diuretic Comparison Project
Background: The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension. Methods: The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data. Results: Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide. Conclusions: The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e046142
Open AccessPer‐Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention—Diuretic Comparison Project
Background: The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension. Methods: The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data. Results: Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide. Conclusions: The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1)
Developing and evaluating per-protocol adherence definitions in a large pragmatic clinical trial: insights from the Diuretic Comparison Project
Objectives: Pragmatic clinical trials leveraging real-world data, such as the Diuretic Comparison Project (DCP), present unique challenges in measuring treatment adherence compared to traditional randomized controlled trials. In DCP, medications were managed through routine VA care and monitored via pharmacy claims, requiring tailored methods to assess adherence beyond standard measures like medication possession ratio (MPR). To develop a data-driven approach to define protocol treatment adherence for pragmatic comparative effectiveness trials. Methods: Structured EHR pharmacy dispense records guided categorization of treatment changes for two diuretics – chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). We examined fill intervals, total drug supply, filling patterns among others to identify prescribing characteristics informing medication adherence definitions and time censoring for per-protocol analysis. Results: Nonadherence was defined as having a gap (>90-days pause in assigned treatment), switch (receiving the other study medication), or discontinuation (without CTD/HCTZ for >90-days). 5,476 patients met nonadherence criteria – 2,851 (52 %) in CTD and 2,625 (48 %) in HCTZ. Switching occurred earlier in CTD patients, gaps were more common in HCTZ, but discontinuation was similar between groups. Conclusions: Defining adherence requires complex decision-making hybrid framework entailing both clinical and statistical expertise. Pragmatic studies should allow flexibility to generate data-driven, clinically-sensitive measures that appropriately describe trial compliance.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1)
Open AccessDeveloping and evaluating per-protocol adherence definitions in a large pragmatic clinical trial: insights from the Diuretic Comparison Project
Objectives: Pragmatic clinical trials leveraging real-world data, such as the Diuretic Comparison Project (DCP), present unique challenges in measuring treatment adherence compared to traditional randomized controlled trials. In DCP, medications were managed through routine VA care and monitored via pharmacy claims, requiring tailored methods to assess adherence beyond standard measures like medication possession ratio (MPR). To develop a data-driven approach to define protocol treatment adherence for pragmatic comparative effectiveness trials. Methods: Structured EHR pharmacy dispense records guided categorization of treatment changes for two diuretics – chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). We examined fill intervals, total drug supply, filling patterns among others to identify prescribing characteristics informing medication adherence definitions and time censoring for per-protocol analysis. Results: Nonadherence was defined as having a gap (>90-days pause in assigned treatment), switch (receiving the other study medication), or discontinuation (without CTD/HCTZ for >90-days). 5,476 patients met nonadherence criteria – 2,851 (52 %) in CTD and 2,625 (48 %) in HCTZ. Switching occurred earlier in CTD patients, gaps were more common in HCTZ, but discontinuation was similar between groups. Conclusions: Defining adherence requires complex decision-making hybrid framework entailing both clinical and statistical expertise. Pragmatic studies should allow flexibility to generate data-driven, clinically-sensitive measures that appropriately describe trial compliance.
- Open Access
- 12 November 2025
- Published by MDPI AG in Information
- Vol. 16 (11) , 978
Estimating the Utility of Using Structured and Unstructured Data for Extracting Incidents of External Hospitalizations from Patient Documents
Patients within the US Department of Veterans Affairs (VA) healthcare system have the option of receiving care at facilities external to the VA network. This work presents a method for identifying external hospitalizations among the VA’s patient population by utilizing data stored in patient records. The process of extracting this information is complicated by the fact that indicators of external hospitalizations come from two sources: well-defined structured data and free-form unstructured text. Though natural language processing (NLP) leveraging Large Language Models (LLMs) has advanced capabilities to automate information extraction from free text, deploying these systems remains complex and costly. Using structured data is low-cost, but its utility must be determined in order to optimally allocate resources. We describe a method for estimating the utility of using structured and unstructured data and show that if specific conditions are met, the level of effort to perform this estimate can be greatly reduced. For external hospitalizations in the VA, our analysis showed that 44.4% of cases identified using unstructured data could not be found using structured data alone.
- 12 November 2025
- Published by MDPI AG in Information
- Vol. 16 (11) , 978
Open AccessEstimating the Utility of Using Structured and Unstructured Data for Extracting Incidents of External Hospitalizations from Patient Documents
Patients within the US Department of Veterans Affairs (VA) healthcare system have the option of receiving care at facilities external to the VA network. This work presents a method for identifying external hospitalizations among the VA’s patient population by utilizing data stored in patient records. The process of extracting this information is complicated by the fact that indicators of external hospitalizations come from two sources: well-defined structured data and free-form unstructured text. Though natural language processing (NLP) leveraging Large Language Models (LLMs) has advanced capabilities to automate information extraction from free text, deploying these systems remains complex and costly. Using structured data is low-cost, but its utility must be determined in order to optimally allocate resources. We describe a method for estimating the utility of using structured and unstructured data and show that if specific conditions are met, the level of effort to perform this estimate can be greatly reduced. For external hospitalizations in the VA, our analysis showed that 44.4% of cases identified using unstructured data could not be found using structured data alone.
- Open Access
- 27 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2710
Social Determinants of Health ICD-10 Code Use by a Large Integrated Healthcare System
Background/Objectives: Identifying social determinants of health (SDOH) is important for effective clinical care. The ICD-10 introduced diagnostic categories to describe patients’ adverse SDOH, but these codes are infrequently used across health systems, presenting challenges to implement data-driven healthcare. This study illustrates SDOH code utilization within a setting that is recognized as one of the largest integrated healthcare systems across the United States. Methods: Real-world clinical data were used with ICD-10 SDOH records obtained from 13,523 participants randomized into the Diuretic Comparison Project, a pragmatic trial conducted within the Veterans Affairs (VA) Health Care System between 2016 and 2022. SDOH code utilization was assessed across study years and among the specialized outpatient clinics. Results: A total of 29,305 SDOH records were identified, and 99.2% were from outpatient encounters. Social, mental, and housing care services generated the most SDOH records. Moreover, 3894 (28.8%) participants had at least one SDOH record during the 6-year period. Particular, 6.9% of participants had a record in the first year, and this increased to 7.6%, 8.1%, 8.7%, 9.6%, 10.3% in consecutive years. Conclusions: Our results suggest that SDOH code utilization has continued to improve within the VA, but SDOH assessments may not occur annually or be performed systematically within an integrated health setting. Much work is needed to develop universal screening tools and mandate routine SDOH evaluations. Nevertheless, a persistent increase in the counts of ICD-10 SDOH records shows a positive movement towards systematic documentation, supporting service providers to efficiently identify patients with adverse SDOH.
- 27 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2710
Open AccessSocial Determinants of Health ICD-10 Code Use by a Large Integrated Healthcare System
Background/Objectives: Identifying social determinants of health (SDOH) is important for effective clinical care. The ICD-10 introduced diagnostic categories to describe patients’ adverse SDOH, but these codes are infrequently used across health systems, presenting challenges to implement data-driven healthcare. This study illustrates SDOH code utilization within a setting that is recognized as one of the largest integrated healthcare systems across the United States. Methods: Real-world clinical data were used with ICD-10 SDOH records obtained from 13,523 participants randomized into the Diuretic Comparison Project, a pragmatic trial conducted within the Veterans Affairs (VA) Health Care System between 2016 and 2022. SDOH code utilization was assessed across study years and among the specialized outpatient clinics. Results: A total of 29,305 SDOH records were identified, and 99.2% were from outpatient encounters. Social, mental, and housing care services generated the most SDOH records. Moreover, 3894 (28.8%) participants had at least one SDOH record during the 6-year period. Particular, 6.9% of participants had a record in the first year, and this increased to 7.6%, 8.1%, 8.7%, 9.6%, 10.3% in consecutive years. Conclusions: Our results suggest that SDOH code utilization has continued to improve within the VA, but SDOH assessments may not occur annually or be performed systematically within an integrated health setting. Much work is needed to develop universal screening tools and mandate routine SDOH evaluations. Nevertheless, a persistent increase in the counts of ICD-10 SDOH records shows a positive movement towards systematic documentation, supporting service providers to efficiently identify patients with adverse SDOH.
- Open Access
- 23 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e279
Development of a feasible and portable electronic flag for near-real-time identification of renal replacement therapy in the Veterans Health Administration
Background: Chronic kidney disease (CKD) is prevalent among US Veterans. Identifying patients undergoing dialysis in real-time is crucial for implementing patient safety measures, including stewardship interventions, such as medication dosing adjustments. Limited feasible and accurate tools exist for near-real-time identification. This study aimed to develop a renal replacement therapy (RRT) flag using structured data in the Veterans Health Administration (VHA) electronic health record (EHR). Methods: Data from Veterans who underwent cardiovascular implantable electronic device (CIED) procedures (9/2015–12/2019) were linked to US Renal Data Systems (USRDS) data. Potential identifiers included outpatient hemodialysis procedure records, community care hemodialysis consults, ICD-10 diagnoses, and serum creatinine (SCr) >4 mg/dL. USRDS served as the comparison standard, and sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Logistic regression determined the area under the curve (AUC). Results: Among 37,706 CIED procedures on 34,994 Veterans, 967 patients (2.6%) were identified by USRDS as ever receiving RRT (hemodialysis and peritoneal dialysis or transplant), with 520 (1.4%) actively receiving RRT at the time of CIED. The RRT flag, combining ≥4 outpatient procedures in the prior 30 days, ≥1 consult in the prior year, and/or SCr >4 mg/dL, achieved an AUC of 0.976 (95% CI: 0.97–0.98), with high sensitivity (0.96; 95% CI: 0.94–0.97) and specificity (0.99; 95% CI: 0.99–1.00). The PPV was 0.70 (95% CI: 0.67–0.74). Performance was slightly lower when consults were replaced with ICD codes. Conclusions: We developed an accurate electronic flag using structured data to identify active RRT within VHA among Veterans undergoing invasive procedures, supporting patient safety and care adjustments. This flag addresses a crucial patient safety gap and supports expansion of stewardship efforts.
- 23 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e279
Open AccessDevelopment of a feasible and portable electronic flag for near-real-time identification of renal replacement therapy in the Veterans Health Administration
Background: Chronic kidney disease (CKD) is prevalent among US Veterans. Identifying patients undergoing dialysis in real-time is crucial for implementing patient safety measures, including stewardship interventions, such as medication dosing adjustments. Limited feasible and accurate tools exist for near-real-time identification. This study aimed to develop a renal replacement therapy (RRT) flag using structured data in the Veterans Health Administration (VHA) electronic health record (EHR). Methods: Data from Veterans who underwent cardiovascular implantable electronic device (CIED) procedures (9/2015–12/2019) were linked to US Renal Data Systems (USRDS) data. Potential identifiers included outpatient hemodialysis procedure records, community care hemodialysis consults, ICD-10 diagnoses, and serum creatinine (SCr) >4 mg/dL. USRDS served as the comparison standard, and sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Logistic regression determined the area under the curve (AUC). Results: Among 37,706 CIED procedures on 34,994 Veterans, 967 patients (2.6%) were identified by USRDS as ever receiving RRT (hemodialysis and peritoneal dialysis or transplant), with 520 (1.4%) actively receiving RRT at the time of CIED. The RRT flag, combining ≥4 outpatient procedures in the prior 30 days, ≥1 consult in the prior year, and/or SCr >4 mg/dL, achieved an AUC of 0.976 (95% CI: 0.97–0.98), with high sensitivity (0.96; 95% CI: 0.94–0.97) and specificity (0.99; 95% CI: 0.99–1.00). The PPV was 0.70 (95% CI: 0.67–0.74). Performance was slightly lower when consults were replaced with ICD codes. Conclusions: We developed an accurate electronic flag using structured data to identify active RRT within VHA among Veterans undergoing invasive procedures, supporting patient safety and care adjustments. This flag addresses a crucial patient safety gap and supports expansion of stewardship efforts.
- Open Access
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5695
Medication Adherence in the Real World: Lessons from the Diuretic Comparison Project
Background/Objectives: Antihypertensive treatment is crucial for preventing major adverse cardiovascular events, but suboptimal adherence remains a challenge. Methods: This is a secondary analysis of routine care data from a large pragmatic trial comparing two thiazide diuretics: chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). In the trial, 13,523 older hypertensive patients were randomized from 72 Veterans Affairs medical centers. Medication possession ratio (MPR), reflecting adherence to either study medication (CTD or HCTZ), was used and compared across all randomized patients. Results: The overall median MPR was 95% for all randomized patients and 80% for 6656 individuals who reached 2.4 years for the average follow-up. Lower MPR was observed in Black, separated, urban-living, and comorbid patients. About 30% of the participants (n = 4022) were categorized as non-adherent using a definition of MPR < 80%. Those with baseline systolic blood pressure ≥ 136, recent smoking history, and prior heart failure and Black participants had decreased odds of having an MPR ≥ 80%, while increased odds of reaching that threshold were observed in those who had an eGFR ≥ 60, received ≥3 antihypertensive medications, were married, or resided in rural areas. Conclusions: This analysis provided assessment of real-world medication adherence in a sizable older hypertensive cohort. The proportion of non-adherence found in our analysis was comparable to national trends for US older adults taking blood pressure medications. Identifying sociodemographic characteristics and health conditions associated with non-adherence can help clinicians design targeted interventions for improved adherence to clinically prescribed medications. This is important as hypertension and the older adult population are both expected to grow significantly in the future.
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5695
Open AccessMedication Adherence in the Real World: Lessons from the Diuretic Comparison Project
Background/Objectives: Antihypertensive treatment is crucial for preventing major adverse cardiovascular events, but suboptimal adherence remains a challenge. Methods: This is a secondary analysis of routine care data from a large pragmatic trial comparing two thiazide diuretics: chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). In the trial, 13,523 older hypertensive patients were randomized from 72 Veterans Affairs medical centers. Medication possession ratio (MPR), reflecting adherence to either study medication (CTD or HCTZ), was used and compared across all randomized patients. Results: The overall median MPR was 95% for all randomized patients and 80% for 6656 individuals who reached 2.4 years for the average follow-up. Lower MPR was observed in Black, separated, urban-living, and comorbid patients. About 30% of the participants (n = 4022) were categorized as non-adherent using a definition of MPR < 80%. Those with baseline systolic blood pressure ≥ 136, recent smoking history, and prior heart failure and Black participants had decreased odds of having an MPR ≥ 80%, while increased odds of reaching that threshold were observed in those who had an eGFR ≥ 60, received ≥3 antihypertensive medications, were married, or resided in rural areas. Conclusions: This analysis provided assessment of real-world medication adherence in a sizable older hypertensive cohort. The proportion of non-adherence found in our analysis was comparable to national trends for US older adults taking blood pressure medications. Identifying sociodemographic characteristics and health conditions associated with non-adherence can help clinicians design targeted interventions for improved adherence to clinically prescribed medications. This is important as hypertension and the older adult population are both expected to grow significantly in the future.
- Open Access
- 23 April 2025
- Published by Springer Nature in BMC Primary Care
- Vol. 26 (1) , 1-9
Provider experiences with and attitudes about an embedded pragmatic clinical trial
Background/aims: The Diuretic Comparison Project (DCP) was a pragmatic clinical trial comparing rates of cardiovascular events between hydrochlorothiazide or chlorthalidone. VA primary care providers (PCPs) and their patients were participants in the study. Veterans ≥ 65 years taking hydrochlorothiazide were randomized to continue on hydrochlorothiazide or switch to chlorthalidone. Participating providers could decline the randomization of their patients. Providers were surveyed about their experience with DCP, and to ascertain providers’ understanding of and attitudes towards embedded pragmatic trials. Methods: A questionnaire was emailed to PCPs that provided informed consent to participate in the study. The survey asked about provider experience with the trial including interest in the study question, awareness of the study and educational materials, impact on the provider-patient relationship, burden of study participation, and their attitudes towards pragmatic trials. Respondents could also add free text comments. Results: There were 180 completed surveys. Of those, most found the trial question of interest (91%) and found the time required to participate in the trial was reasonable (67%). Only 2 (1%) felt the study had a negative impact on the provider-patient relationship. 97% of providers were as comfortable with (59%) or more comfortable with (32%) DCP compared to traditional randomized controlled trials. Conclusion: Responding providers’ experience with DCP and their attitudes towards pragmatic trials were positive. Primary care providers indicated willingness to participate in future pragmatic trials if burden is low and it does not negatively impact patient care. Results support continued use of pragmatic embedded clinical trials in primary care. Clinical trial registration: NCT02185417. Registered 9 July 2014. https://clinicaltrials.gov/ct2/show/NCT02185417.
- 23 April 2025
- Published by Springer Nature in BMC Primary Care
- Vol. 26 (1) , 1-9
Open AccessProvider experiences with and attitudes about an embedded pragmatic clinical trial
Background/aims: The Diuretic Comparison Project (DCP) was a pragmatic clinical trial comparing rates of cardiovascular events between hydrochlorothiazide or chlorthalidone. VA primary care providers (PCPs) and their patients were participants in the study. Veterans ≥ 65 years taking hydrochlorothiazide were randomized to continue on hydrochlorothiazide or switch to chlorthalidone. Participating providers could decline the randomization of their patients. Providers were surveyed about their experience with DCP, and to ascertain providers’ understanding of and attitudes towards embedded pragmatic trials. Methods: A questionnaire was emailed to PCPs that provided informed consent to participate in the study. The survey asked about provider experience with the trial including interest in the study question, awareness of the study and educational materials, impact on the provider-patient relationship, burden of study participation, and their attitudes towards pragmatic trials. Respondents could also add free text comments. Results: There were 180 completed surveys. Of those, most found the trial question of interest (91%) and found the time required to participate in the trial was reasonable (67%). Only 2 (1%) felt the study had a negative impact on the provider-patient relationship. 97% of providers were as comfortable with (59%) or more comfortable with (32%) DCP compared to traditional randomized controlled trials. Conclusion: Responding providers’ experience with DCP and their attitudes towards pragmatic trials were positive. Primary care providers indicated willingness to participate in future pragmatic trials if burden is low and it does not negatively impact patient care. Results support continued use of pragmatic embedded clinical trials in primary care. Clinical trial registration: NCT02185417. Registered 9 July 2014. https://clinicaltrials.gov/ct2/show/NCT02185417.
- 19 November 2024
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 148, 107755
Characteristics of VA hospitals by participation status in a large pragmatic embedded clinical trial
- 19 November 2024
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 148, 107755
Characteristics of VA hospitals by participation status in a large pragmatic embedded clinical trial